CanBas Co., Ltd. (TYO:4575)

Japan flag Japan · Delayed Price · Currency is JPY
1,025.00
-20.00 (-1.91%)
Aug 8, 2025, 3:30 PM JST
-1.91%
Market Cap19.59B
Revenue (ttm)n/a
Net Income (ttm)-1.16B
Shares Out19.11M
EPS (ttm)-61.09
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume201,000
Average Volume213,890
Open1,034.00
Previous Close1,045.00
Day's Range1,015.00 - 1,034.00
52-Week Range486.00 - 1,512.00
Beta-1.21
RSI51.75
Earnings DateAug 8, 2025

About ATSG

CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 11
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4575
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.